EGeen announced its nomination of the 2009 Baltic Corporate Citizen Award
Mountain View, CA, March 30, 2009 - EGeen International Corporation announced that the Company has been chosen as the recipient of “Baltic Corporate Citizen Award” by The U.S-Baltic Foundation. It will be honored at the USBF gala weekend on May 15-16 at the Mayflower Hotel, 1127 Connecticut Ave NW, which has become the premiere annual event in Washington, DC for American friends of Estonia, Latvia and Lithuania. "This nomination is a very important recognition of our work on developing scientific and business ties between the dynamically developing healthcare sectors of both the US and the Baltic states," said Kalev Kask, PhD, EGeen's President and CEO. "We are delighted to receive this prestigious Award and we are quite certain it will motivate us to redouble our efforts of the valuable exchange between the US and the Baltic states." EGeen is a transatlantic CRO whose key business focus is to advance the drug development of biotech and pharmaceutical clients via expeditious and high quality yet cost-effective clinical trials. Headquartered in California since its inception in 2001, EGeen has wholly owned subsidiaries in Estonia, Ukraine and Romania with operations in several Eastern European and Scandinavian countries and Turkey. It was funded by premier US and international venture capital and private equity funds, and currently employs 50 people in the US and Europe in marketing, clinical trial management and monitoring, QA, logistics and IT support. Kalev Kask, PhD |